ArticleACS omega2024
EVQ-218: Characterization of High-Energy Nanoparticles that Measure up to NIST Standards.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Escaping the ESKAPE Antimicrobial Resistant Cycle with EVQ-218.Antibiotics (Basel, Switzerland) · 2026Article
- An in vitro study on macrophage toxicity of allotrope silver nanoparticles.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EVQ-218 is a high-energy produced nanoparticle (NP) with a method of manufacture that avoids chemical or biological synthesis. The patented single-step process generates stable, pure metal NPs directly into HPLC grade water. Laser ablation via the multiple cross laser system occurs at a rate that is in the region of dielectric breakdown, generating temperatures and pressures akin to those of diamond formation. The spherical particles from this method have an ultrastable shell structure that inhibits the hallmark ion emission that occurs in other nanosilver species. The resulting particle size distribution is so narrow that additional size refinement or stabilizing chemistries are not necessary. These properties make EVQ-218 an attractive clean and green alternative to traditional nanosilvers, particularly when factoring in shelf life, as EVQ-218 maintains (uniform) stability for years, while NIST standard materials degrade within a few weeks. EVQ-218 characterization and differentiation are timely as the rise of antimicrobial resistance has caused a surge of research on antimicrobial silver NPs. It has been widely established that the antimicrobial activity of nanosilver is due to ion emission. Unfortunately, metal ions can be quite toxic and prevent certain biomedical and consumer product applications. In an ever-changing regulatory landscape, there is increasing scrutiny to definitively characterize nanomaterials and assess their potential environmental/toxicological footprint. EVQ-218 was characterized alongside comparable NIST standard NPs, with particular interest in speciation and fate. Particle characterization studies reveal that EVQ-218 is nearly equivalent to NIST standard material with respect to particle morphology and uniformity. Dissolution and surface chemistry studies quickly differentiate EVQ-218 as the first stable, nonemissive, pure metal NP that is on par with NIST standards for ideal materials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.